Naproxen inhibits spontaneous lung adenocarcinoma formation in KrasG12V mice

Naproxen inhibits spontaneous lung adenocarcinoma formation in KrasG12V mice

Lung cancer is the leading cause of cancer related deaths worldwide. The present study investigated the effects of naproxen (NSAID) on lung adenocarcinoma in spontaneous lung cancer mouse model. Six-week-old transgenic KrasG12V mice (n = 20; male + female) were fed modified AIN-76A diets containing...

Full description

Bibliographic Details
Main Authors:	Gaurav Kumar, Venkateshwar Madka, Anil Singh, Mudassir Farooqui, Nicole Stratton, Stanley Lightfoot, Altaf Mohammed, Chinthalapally V. Rao
Format:	Article
Language:	English
Published:	Elsevier 2021-06-01
Series:	Neoplasia: An International Journal for Oncology Research
Subjects:	Lung cancer Prevention Naproxen KrasG12V Lung adenocarcinoma NSAID
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558621000361

Similar Items

Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead
by: Hui-yu Li, et al.
Published: (2023-03-01)

Recent Advances in the Synthesis of Ibuprofen and Naproxen
by: Min-Woo Ha, et al.
Published: (2021-08-01)

RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS‐mutated lung adenocarcinoma
by: Hong‐Shuai Li, et al.
Published: (2023-05-01)

Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer
by: Ali Chour, et al.
Published: (2024-09-01)

A case report of high-grade fetal lung adenocarcinoma with KRAS mutation
by: Wang Jiaqi, et al.
Published: (2024-01-01)

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients
by: Veronica Aran, et al.
Published: (2021-09-01)

KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
by: Judit Moldvay, et al.
Published: (2024-01-01)

An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
by: Berardino Prencipe, et al.
Published: (2023-06-01)

Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors
by: Kai Wang, et al.
Published: (2024-12-01)

MVK, induced by Kras, represses cGAS-Sting signalling in lung adenocarcinoma
by: Changsheng Zhou, et al.
Published: (2025-01-01)

Early detection of pre-malignant lesions in a KRASG12D-driven mouse lung cancer model by monitoring circulating free DNA
by: Callum P. Rakhit, et al.
Published: (2019-02-01)

Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma
by: Hui ZHANG, et al.
Published: (2015-11-01)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
by: Maria Colombino, et al.
Published: (2019-11-01)

The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma
by: Shangshang Ma, et al.
Published: (2024-12-01)

Novel insights into the RTK-dependent metastatic phenotype of KRAS-mutant lung adenocarcinoma
by: Mariana Cooke
Published: (2021-11-01)

Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma
by: Masaoki Ito, et al.
Published: (2023-03-01)

Editorial: KRAS in stage IV non-small cell lung cancer
by: Anneloes L. Noordhof, et al.
Published: (2025-03-01)

SMARCA4 mutations in KRAS‐mutant lung adenocarcinoma: a multi‐cohort analysis
by: Liang Liu, et al.
Published: (2021-02-01)

The KRASG12C inhibitors in lung cancer therapy
by: Maciej Jędrak, et al.
Published: (2023-09-01)

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer
by: W. J. McDaid, et al.
Published: (2024-11-01)

Genome-Wide and Phenotypic Evaluation of Stem Cell Progenitors Derived From Gprc5a-Deficient Murine Lung Adenocarcinoma With Somatic Kras Mutations
by: Reem Daouk, et al.
Published: (2019-04-01)

Copper(II) and Platinum(II) Naproxenates: Insights on Synthesis, Characterization and Evaluation of Their Antiproliferative Activities
by: Amanda A. Silva, et al.
Published: (2023-08-01)

Establishing the mutational effect on the binding susceptibility of AMG510 to KRAS switch II binding pocket: Computational insights
by: Abdul Rashid Issahaku, et al.
Published: (2022-01-01)

Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
by: Zhang S, et al.
Published: (2021-10-01)

Targeting KRAS mutant lung cancer: light at the end of the tunnel
by: Matthias Drosten, et al.
Published: (2022-03-01)

Resistance to KRAS inhibition in advanced non-small cell lung cancer
by: Katherina Bernadette Sreter, et al.
Published: (2024-05-01)

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
by: Lucía Notario, et al.
Published: (2023-10-01)

FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling
by: Marion Morel, et al.
Published: (2024-03-01)

Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma
by: Qi Wang, et al.
Published: (2023-10-01)

Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis
by: Qi-An Chen, et al.
Published: (2024-02-01)

CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code
by: Zhang SS, et al.
Published: (2023-04-01)

KRAS inhibitors: going noncovalent
by: Matthias Drosten, et al.
Published: (2022-12-01)

Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models
by: Daniel J. Sisler, et al.
Published: (2023-02-01)

A Potential Biomarker of Combination of Tumor Mutation Burden and Copy Number Alteration for Efficacy of Immunotherapy in KRAS-Mutant Advanced Lung Adenocarcinoma
by: Luochengling Xiang, et al.
Published: (2020-09-01)

TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS, STK11 and KEAP1 mutations
by: Armin Frille, et al.
Published: (2024-04-01)

ZNF24 regulates the progression of KRAS mutant lung adenocarcinoma by promoting SLC7A5 translation
by: Daqi Jia, et al.
Published: (2022-11-01)

Pneumonic-type lung adenocarcinoma with KRAS G12V mutation and sustained response to Afatinib
by: Jie Zhao, et al.
Published: (2024-04-01)

Apoptosis-inducing activity of synthetic hydrocarbon-stapled peptides in H358 cancer cells expressing KRASG12C
by: Cuicui Li, et al.
Published: (2021-09-01)

Corrigendum: TP53 co-mutations in advanced lung adenocarcinoma: comparative bioinformatic analyses suggest ambivalent character on overall survival alongside KRAS, STK11 and KEAP1 mutations
by: Armin Frille, et al.
Published: (2024-09-01)

Pharmacological effects of a synthetic quinoline, a hybrid of tomoxiprole and naproxen, against acute pain and inflammation in mice: a behavioral and docking study
by: Hossein Hosseinzadeh, et al.
Published: (2017-04-01)